<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460263</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01</org_study_id>
    <nct_id>NCT02460263</nct_id>
  </id_info>
  <brief_title>The EvAluation of TaBlo In-CLinic and In-HOme</brief_title>
  <acronym>TABLO</acronym>
  <official_title>A Prospective Multicenter, Open Label, Non-Randomized, Cross-Over Study Evaluating the Use of the Tablo Hemodialysis System In-Center and In-Home by Subjects With End Stage Renal Disease (ESRD) Who Are on Stable Dialysis Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Outset Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Outset Medical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Tablo Hemodialysis System when used In-Center by
      trained individuals and In-Home by trained Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects will be enrolled in the trial for approximately 21 weeks according to the following schedule:
Run-in, In-Center - Subjects undergo study staff administered dialysis treatment 4 times/week for 1 week
Treatment Period 1, In-Center - Subjects undergo study staff administered dialysis treatment 4 times/week for 32 treatments (approximately 8 weeks)
In-Home Transition - Subjects undergo device training for the study, perform self-care dialysis 4 times/week for approximately 4 weeks, and are assessed for stability in the new care environment.
Treatment Period 2, In-Home - Subjects undergo self-care dialysis treatment 4 times/week for 32 treatments (approximately 8 weeks)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly Standardized Dialysis Adequacy</measure>
    <time_frame>8 weeks per period</time_frame>
    <description>Weekly standardized dialysis adequacy (stdKt/V) was measured using the second-generation formula of Daugirdas. This formula normalizes urea clearance among heterogeneous hemodialysis schedules, where K=dialyzer clearance or urea, t=treatment time, and V=subject's volume of urea distribution. stdKt/V values of ≥ 2.1 are regarded as being adequate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Pre-Specified Adverse Events</measure>
    <time_frame>8 weeks per period</time_frame>
    <description>All adverse events (AEs) observed in the trial were reviewed by an independent Clinical Events Committee (CEC). AEs adjudicated into the following pre-specified categories were included in the outcome measure:
Serious Adverse Event
Allergic Reaction: to dialyzer, blood tubing or chemical disinfectant.
Blood Loss: that leads to death, transfusion or fluid resuscitation with greater than 1 liter of crystalloid IV fluids.
Hemolytic Reaction: due to disinfectant exposure, dialysate temperature, mechanical failure or other device related causes.
Infection: any infection related to catheter, its tunnel or exit site, AV fistula, or AV graft.
Intra-Dialysis Event: a significant clinical event such as loss of consciousness, cardiac arrest, or seizure caused by device failure.
Vascular Access Complications
Pyrogenic Reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrafiltration Rate Success</measure>
    <time_frame>8 weeks per period</time_frame>
    <description>The Ultrafiltration (UF) rate was calculated using the following method:
UF rate = (Fluid Removal Goal + Rinse Back Volume) / Treatment Duration.
Where: Fluid Removal Goal = (Today's Weight - Prescribed Estimated Dry Weight)
And: Rinse Back Volume = The volume of saline, 300mL, returned to the patient at the end of treatment.
Each dialysis treatment was flagged as a success with respect to UF if the actual UF rate was within 10% of the prescribed UF rate. The mean (i.e., success proportion) and standard deviation were computed by treatment period across all subjects, where the denominator for the mean calculations was the total number of treatments in each treatment period for which the subjects contributed non-missing UF data.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>In-Center</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Staff administered treatments in-center using the device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Home</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient administered treatments in-home using the device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tablo Hemodialysis System</intervention_name>
    <arm_group_label>In-Center</arm_group_label>
    <arm_group_label>In-Home</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has end stage renal disease (ESRD) adequately treated by maintenance dialysis
             achieving a Kt/V ≥ 1.2 and has been deemed stable for at least three months by his/her
             treating nephrologist.

          -  Subject has a well-functioning and stable vascular access that allows a blood flow of
             at least 300 ml/min.

        Exclusion Criteria:

          -  Life expectancy less than 12 months from first study procedure.

          -  Subject has had a recent major cardiovascular adverse event within the last 3 months.

          -  Subject has New York Class III or IV Congestive Heart Failure, or ejection fraction
             less than 30%.

          -  Subject with fluid overload due to intractable ascites secondary to liver cirrhosis.

          -  Subject has uncontrolled blood pressure.

          -  Subject is intolerant to heparin.

          -  Subject is seroreactive for Hepatitis B Surface Antigen.

          -  Subject has an active, life-threatening, rheumatologic disease.

          -  Subject has a history of adverse reactions to dialyzer membrane material.

          -  Subject is expected to receive an organ transplant during the course of the study.

          -  Subject has a life-threatening malignancy actively receiving treatment that would
             prevent successful completion of the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Outset Medical</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <results_first_submitted>May 27, 2020</results_first_submitted>
  <results_first_submitted_qc>June 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2020</results_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02460263/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02460263/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at 8 dialysis centers throughout the U.S.</recruitment_details>
      <pre_assignment_details>A run-in period of 1 week (4 hemodialysis treatments) was required on the Tablo Hemodialysis System prior to the first period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>In-Center Dialysis, Then In-Home Dialysis</title>
          <description>Subjects first entered the In-Center period of the trial before transitioning to the In-Home period. Dialysis treatments were based on physician prescription (clearance and volume targets) and included the following schedules:
Treatment Period 1, In-Center – Subjects received study staff administered dialysis treatment 4 times/week for 32 treatments (approximately 8 weeks)
In-Home Transition– Subjects received device training and performed self-care dialysis 4 times/week for approximately 4 weeks, and were assessed for stability in the new care environment.
Treatment Period 2, In-Home – Subjects received self-care dialysis treatment 4 times/week for 32 treatments (approximately 8 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>In-Center Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Transition Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>In-Home Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intention-To-Treat (ITT) Population</title>
          <description>The ITT population was defined as all participants who were enrolled and fulfilled inclusion criteria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vascular Access Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Fistula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Catheter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weekly Standardized Dialysis Adequacy</title>
        <description>Weekly standardized dialysis adequacy (stdKt/V) was measured using the second-generation formula of Daugirdas. This formula normalizes urea clearance among heterogeneous hemodialysis schedules, where K=dialyzer clearance or urea, t=treatment time, and V=subject's volume of urea distribution. stdKt/V values of ≥ 2.1 are regarded as being adequate.</description>
        <time_frame>8 weeks per period</time_frame>
        <population>Intention-to-treat (ITT) population with no imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>In-Center</title>
            <description>Staff administered hemodialysis treatments for participants 4 times per week for 8 weeks In-Center using the Tablo system</description>
          </group>
          <group group_id="O2">
            <title>In-Home</title>
            <description>Participants administered hemodialysis treatments In-Home using the Tablo system</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Standardized Dialysis Adequacy</title>
          <description>Weekly standardized dialysis adequacy (stdKt/V) was measured using the second-generation formula of Daugirdas. This formula normalizes urea clearance among heterogeneous hemodialysis schedules, where K=dialyzer clearance or urea, t=treatment time, and V=subject's volume of urea distribution. stdKt/V values of ≥ 2.1 are regarded as being adequate.</description>
          <population>Intention-to-treat (ITT) population with no imputation of missing values.</population>
          <units>Weekly Standardized Kt/V</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.3"/>
                    <measurement group_id="O2" value="2.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Pre-Specified Adverse Events</title>
        <description>All adverse events (AEs) observed in the trial were reviewed by an independent Clinical Events Committee (CEC). AEs adjudicated into the following pre-specified categories were included in the outcome measure:
Serious Adverse Event
Allergic Reaction: to dialyzer, blood tubing or chemical disinfectant.
Blood Loss: that leads to death, transfusion or fluid resuscitation with greater than 1 liter of crystalloid IV fluids.
Hemolytic Reaction: due to disinfectant exposure, dialysate temperature, mechanical failure or other device related causes.
Infection: any infection related to catheter, its tunnel or exit site, AV fistula, or AV graft.
Intra-Dialysis Event: a significant clinical event such as loss of consciousness, cardiac arrest, or seizure caused by device failure.
Vascular Access Complications
Pyrogenic Reaction</description>
        <time_frame>8 weeks per period</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>In-Center</title>
            <description>Staff administered hemodialysis treatments for participants In-Center using the Tablo system</description>
          </group>
          <group group_id="O2">
            <title>In-Home</title>
            <description>Participants administered hemodialysis treatments In-Home using the Tablo system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pre-Specified Adverse Events</title>
          <description>All adverse events (AEs) observed in the trial were reviewed by an independent Clinical Events Committee (CEC). AEs adjudicated into the following pre-specified categories were included in the outcome measure:
Serious Adverse Event
Allergic Reaction: to dialyzer, blood tubing or chemical disinfectant.
Blood Loss: that leads to death, transfusion or fluid resuscitation with greater than 1 liter of crystalloid IV fluids.
Hemolytic Reaction: due to disinfectant exposure, dialysate temperature, mechanical failure or other device related causes.
Infection: any infection related to catheter, its tunnel or exit site, AV fistula, or AV graft.
Intra-Dialysis Event: a significant clinical event such as loss of consciousness, cardiac arrest, or seizure caused by device failure.
Vascular Access Complications
Pyrogenic Reaction</description>
          <population>Safety Population</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ultrafiltration Rate Success</title>
        <description>The Ultrafiltration (UF) rate was calculated using the following method:
UF rate = (Fluid Removal Goal + Rinse Back Volume) / Treatment Duration.
Where: Fluid Removal Goal = (Today's Weight - Prescribed Estimated Dry Weight)
And: Rinse Back Volume = The volume of saline, 300mL, returned to the patient at the end of treatment.
Each dialysis treatment was flagged as a success with respect to UF if the actual UF rate was within 10% of the prescribed UF rate. The mean (i.e., success proportion) and standard deviation were computed by treatment period across all subjects, where the denominator for the mean calculations was the total number of treatments in each treatment period for which the subjects contributed non-missing UF data.</description>
        <time_frame>8 weeks per period</time_frame>
        <population>Intention-to-treat (ITT) population with no imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>In-Center</title>
            <description>Staff administered hemodialysis treatments for participants In-Center using the Tablo system</description>
          </group>
          <group group_id="O2">
            <title>In-Home</title>
            <description>Participants administered hemodialysis treatments In-Home using the Tablo system</description>
          </group>
        </group_list>
        <measure>
          <title>Ultrafiltration Rate Success</title>
          <description>The Ultrafiltration (UF) rate was calculated using the following method:
UF rate = (Fluid Removal Goal + Rinse Back Volume) / Treatment Duration.
Where: Fluid Removal Goal = (Today's Weight - Prescribed Estimated Dry Weight)
And: Rinse Back Volume = The volume of saline, 300mL, returned to the patient at the end of treatment.
Each dialysis treatment was flagged as a success with respect to UF if the actual UF rate was within 10% of the prescribed UF rate. The mean (i.e., success proportion) and standard deviation were computed by treatment period across all subjects, where the denominator for the mean calculations was the total number of treatments in each treatment period for which the subjects contributed non-missing UF data.</description>
          <population>Intention-to-treat (ITT) population with no imputation of missing values.</population>
          <units>Percentage of Dialysis Treatments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected during the following time periods: In-Center Period: 8 weeks Transition Period: 4 weeks In-Home Period: 8 weeks</time_frame>
      <desc>All AEs were required to be reported in the trial and were assessed through participant questionnaires, investigator assessments and laboratory testing.
AEs were reviewed by an independent Clinical Events Committee (CEC) and adjudicated into two categories:
Pre-specified AEs (e.g., SAEs and/or treatment-related events)
Unrelated to Tablo System
Unrelated AEs were fully adjudicated for seriousness / relatedness, but were not assigned a specific AE term (MedDRA).</desc>
      <group_list>
        <group group_id="E1">
          <title>In-Center</title>
          <description>Staff administered hemodialysis treatments for participants 4 times per week for 8 weeks In-Center using the Tablo system</description>
        </group>
        <group group_id="E2">
          <title>Transition Period</title>
          <description>Staff and participant administered hemodialysis treatments using the Tablo system</description>
        </group>
        <group group_id="E3">
          <title>In-Home</title>
          <description>Participants administered hemodialysis treatments In-Home using the Tablo system</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Access Site Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Blood Loss from Dialyzer &amp; Lines</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Unrelated to Tablo System</sub_title>
                <description>Adverse events deemed unrelated to Tablo Hemodialysis System</description>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="14" subjects_affected="9" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations</name_or_title>
      <organization>Outset Medical, Inc</organization>
      <phone>(669) 231-8200</phone>
      <email>clinical@outsetmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

